Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE)

Author： Lindsay R.

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.22, Iss.2, 2011-02, pp. : 447-451

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bazedoxifene: a selective estrogen-receptor modulator

By Mitwally Mohamed FM

Women's Health, Vol. 4, Iss. 4, 2008-07 ,pp. : 319-326

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

By Palacios Santiago

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1553-1563

Informa Healthcare

Access to resources Recommend Favorite

Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis – a clinical update on efficacy and safety

By Deal Chad L Draper Michael W

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 199-210

Future Medicine

Access to resources Recommend Favorite

Selective estrogen receptor modulators

By Petersen Nicole Briggs Amber

Clinical Review in Bone and Mineral Metabolism, Vol. 3, Iss. 1, 2005-03 ,pp. : 19-30

Humana Press, Inc

Access to resources Recommend Favorite

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

By Villiers T. Chines A. Palacios S. Lips P. Sawicki A. Levine A. Codreanu C. Kelepouris N. Brown J.

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 567-576

Springer Publishing Company

Access to resources Recommend Favorite